Hala Ahmed El-Lathy MD, MSc, Presenter: Nothing to Disclose

SAMY EL BADAWAY, Abstract Co-Author: Nothing to Disclose

Yasser Alassiri MD, PhD, Abstract Co-Author: Nothing to Disclose

YASSER ALMALKI, Abstract Co-Author: Nothing to Disclose

Ahlam Dohal, Abstract Co-Author: Nothing to Disclose

EHAB IBRAHIM, Abstract Co-Author: Nothing to Disclose

This study aimed to evaluate the role of pretreatment 18-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) as a predictor of progression free survival (PFS), and overall survival (OS) in breast cancer patients presenting with multiple or oligometastatic disease

After obtaining the institutional review board approval, we conducted a retrospective analysis of metastatic breast cancer patients ( MBC) with ≥1 metastatic lesion on pretreatment PET/CT from 01/01/2010-12/31/2013 . We examined the association between the highest pretreatment (SUVmax) in metastatic sites (bone, liver, lung and lymph nodes )and the treatment outcomes. The (PFS), and (OS) were calculated by the Kaplan-Meier method, and the differences were evaluated on log rank test. The prognostic significance was assessed by univariate and multivariate analyses.

We identified 130 MBC patients with median age of 50.4 years who had pretreatment PET/CT (64.3% ER+ and 21.4% HER2+). Median OS was 34 months. Oligometastasis mainly to bone was observed in 30 patients while multiple metastases was noticed in 100 patients. The receiver-operating characteristic curve (ROC) demonstrated a SUVmax of 7.7 to be the optimal cutoff in patients with multiple metastases for predicting PFS which is significantly higher in patients with pretreatment PET- CT SUVmax ≤ 7.7 compared to > 7.7 (P 4.4 (P =0.001). Similarly, On multivariate analysis, the SUVmax category was the only factor associated with PFS ( (HR) = 7.4 , 95% C I 3.2-56.8, P<0. 026) and but not OS (P=0.77) .

This study shows that the pretreatment SUVmax is a potential independent prognostic predictor of clinical outcomes in metastatic breast cancer patients

The 18- FDG PET CT is feasible , relatively safe imaging with satisfactory sensitivity and specificity in breast cancer patients .

El-Lathy, H, EL BADAWAY, S, Alassiri, Y, ALMALKI, Y, Dohal, A, IBRAHIM, E, The Role of Pretreatment Maximum Standardized Uptake Value of 18 F-FDG (PET/CT)in Predicting Treatment Outcome in Breast Cancer Patients Presenting with Multiple or Oligometastatic Disease.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14007106.html